This edition of Null and Noteworthy highlights results that reveal the difficulty in drawing definitive conclusions from data, including new findings about epidurals that contradict several others and an apparent null result on sex differences that may derive from “circular logic.”

This month’s issue of the Null and Noteworthy newsletter breaks down some negative results involving prenatal exposures, an experimental treatment for Angelman syndrome, and the role that age at autism diagnosis plays in subsequent outcomes, and more.

This month’s newsletter tackles null findings from an attempted replication of a “revolutionary” MRI approach and an analysis of family genetics.

New data from clinical trials of arbaclofen and oxytocin underscore the murkiness of null results. Plus, researchers seek clarity on the neurodevelopmental effects of oxytocin during childbirth.

In this edition of Null and Noteworthy, researchers upend early interventions and diagnostic boundaries.

Studies of behavioral treatments for autism are complex and can easily be misunderstood. Here we provide some guidance.

In this edition of Null and Noteworthy, Spectrum talks with a Nature editor about the journal’s move to publish more null results.

In this edition of Null and Noteworthy, scientists find little to be excited about in research on biomarkers for neurodevelopmental conditions.

This edition takes aim at the autism-intervention evidence base with a slew of null results, plus findings that challenge a prevailing autism brain theory.

This month’s newsletter highlights findings on the use of three medication types during pregnancy.